Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Theragenics suspends palladium-103 seed shipments to Core

Theragenics Corporation said it has suspended shipments of TheraSeed palladium-103 brachytherapy seeds to Core Oncology as the latter failed to pay its trade receivables as agreed in the contract. Theragenics also has provided a notice of termination of its supply and reseller agreement to Core, as part of which Theragenics is the exclusive palladium-103 seed supplier to Core for the treatment of prostate cancer in the US and Canada, since January 2010.

The notice allows a brief transition period during which further orders from Core will be accepted and met.

Theragenics Corporation chairman and CEO Christine Jacobs said that litigation recently filed against Core by a third party led to the current situation.

"We believe there is an unacceptable level of uncertainty surrounding Core’s ability to satisfy their financial obligations to us," Jacobs said.